PIRIBEDIL IN THE TREATMENT OF PATIENTS WITH CHRONIC BRAIN ISCHEMIA AND COGNITIVE DISORDERS

Download full text PDF
Issue: 
4
Year: 
2016

Professor A. Bogolepova, MD; Professor E. Chukanova, MD N.I. Pirogov Russian National Research Medical University, Moscow

Chronic brain ischemia (CBI) is manifested by a set of neuropsychological and neurological symptoms. Cognitive impairments detected in patients with CBI largely determine their state. Just at the earliest stages of CBI, there is abnormal metabolism of mediators, primarily dopaminergic, cholinergic, and glutamatergic ones. One of the drugs that modulate the dopaminergic system is Piribedil (Pronoran) that belongs to nonergolinic dopamine receptor agonists and stimulates D2 and D3 receptors. Numerous trials confirm its safety and efficacy in affecting cognitive, psychoemotional, and motor disorders in patients with CBI.
Keywords: 
neurology
chronic brain ischemia
dopamine
cognitive impairments
anxiety and depressive disorders
Pronoran

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Suslina Z.A., Varakin Ju.Ja., Vereschagin N.V. Sosudistye zabolevanija golovnogo mozga / M., 2009; 350 s.
  2. De Deyn P., Reuck J., Orgogozo J. et al. Nreatment of acute stroke with
  3. puracetam/ Members of the Piracetam in Acute Stroke Stude (PASS) Group // Stroke. – 1997; 12: 2347–52.
  4. Goldstein L., Adams R., Becker K. et al. Ptimary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association // Stroke. – 2001; 32: 280–99.
  5. Lai S., Alter M., Friday G. et al. A multifactorial analysis of risk factors for recurrence of ischemic stroke // Stroke. – 1994; 25: 958–62.
  6. Leppala J., Virtamo J., Fogelholm R. et al. Different risk factors for different stroke subtypes // Stroke. – 1999; 30: 2535–40
  7. Chukanova E.I., Chukanova A.S. Otdel'nye mehanizmy patogeneza formi rovanija nedostatochnosti mozgovogo krovoobraschenija // Farmateka (kardio-logija/nevrologija). – 2014; 13 (286): 14–20.
  8. Jin K., Zhu Y., Sun Y. et al. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo // Proc. Natl. Acad. Sci. USA. – 2002; 99 (18): 11946–50.
  9. Hinderliter A., Caughey M. Assessing endothelial function as a risk factor for cardiovascular disease // Curr. Atheroscler. Rep. – 2003; 5 (6): 506–13.
  10. Yung Y., Rosenberg G. Blood-brain barrier breakdown in acute and chronic cerebrovascular disease // Stroke. – 2011; 42 (11): 3323–8.
  11. Baryshnikov A.Ju., Shishkin Ju.V. Immunologicheskie problemy apop toza / M., 2002; 318.Gomazkov O.A. Nejrohimija ishemicheskih i vozrastnyh patologij 11. mozga / M., 2003; 200 s.
  12. Mattson M. Apoptosis in neurodegenerative disorders // Nature Rev. Mol. Cell Biol. – 2000; 1: 120–9.
  13. Gusev E.I., Skvortsova V.I. Ishemija golovnogo mozga / M. Meditsina, 2001; 326 s.
  14. Gomazkov O.A. Nejrotroficheskie i rostovye faktory mozga: regulja tornaja spetsifika i terapevticheskij potentsial // Uspehi fiziologicheskih nauk. – 2005; 36 (2): 1–25.
  15. Gomazkov O.A. Nejropeptidy i rostovye faktory mozga / M., 2002; 239 s.
  16. Bogolepova A.N., Chukanova E.I. Problema nejroplastichnosti v nevrologii // Zhurn. nevrol. i psihiat. im. S.S. Korsakova. – 2010; 110 (8): 72–5.
  17. Hsieh J., Gage F. Chromatin remodeling in neural development and plasticity // Curr. Opin. Cell Biol. – 2005; 17 (6): 664–71
  18. Semchenko V.V., Stepanov S.S., Bogolepov N.N. Sinapticheskaja plastich- nost' golovnogo mozga / Omsk, 2008.
  19. Marrone D., LeBoutillier J., Petit T. Changes in synaptic ultrastructure during reactive synaptogenesis in the rat dentate gyrus // Brain Research. – 2004; 1005: 124–36.
  20. Jahno N.N., Levin O.S., Damulin I.V. Sopostavlenie klinicheskih i MRT-dannyh pri distsirkuljatornoj entsefalopatii. Kognitivnye narushenija // Nevrol. zhurn. – 2001; 3: 10–8.
  21. Boniton-Kopp C. Prevalence of risk factors for intima-media thickening: A 21. literature revier. Intima-Media Thickness and Atherosclerosis / Predicting the risk? ed. By P.-J. Touboul / Paris, 1996; part 3: p. 27–44.
  22. Massey L. Diary food consumption, blood pressure and stroke // J. Nutr. – 22. 2001; 131: 1875–8.
  23. Aronov D.M. Lechenie i profilaktika ateroskleroza / M.: Triada H, 23. 2002; s. 9. Maier J. Low magnesium and atherosclerosis: an evidence-based link // 24. Mol. Aspects. Med. – 2003; 24: 137–46.
  24. Damulin I.V. Distsirkuljatornaja entsefalopatija v pozhilom i starche skom vozraste. Dis. … d-ra med. nauk. M., 1997
  25. Gan'kina O.A., Vasenina E.E., Vasenina E.D. i dr. Vlijanie piribedila na umerennye kognitivnye narushenija pri distsirkuljatornoj entsefalopatii // Zhurn. nevrol. i psihiat. – 2014; 6 (2): 62–7.
  26. Levin O.S. Kliniko-magnitno-rezonansno-tomograficheskoe issledo vanie distsirkuljatornoj entsefalopatii s kognitivnymi narushenijami. Avtoref. dis. ... kand. med. nauk. M., 1996.
  27. Alard P., Englund E., Marcusson J. Caudate nucleus dopamine D2 receptors . in vascular dementia // Dementia and Geriatric Cognitive Disorders. – 2002; 14: 22–5.
  28. Jahno N.N., Zaharov V.V., Lokshina A.B. Sindrom umerennyh kognitiv- nyh narushenij pri distsirkuljatornoj entsefalopatii // Zhurn. nevrol. i psihiat. – 2005; 105 (2): 13–7.
  29. Nagaraja D., Jayaashree S. Randomized study of the dopamine receptor agonist piribedil in the treatment of mild cognitive impairment // Am. J. Psychiatry. – 2001; 158: 1517–9.
  30. Court J., Perry E., Kalaria R. Neurotransmitter changes in vascular dementia. Cerebrovascular disease, cognitive impairment and dementia. Eds. J. O’Brien et al. / London: Martin Dunitz, 2004; 133–52.
  31. Alard P., Englund E., Marcusson J. Reduced number of caudate nucleus dopamine uptake sites in vascular dementia // Dementia. – 1999; 10: 77–80.
  32. Pantoni L., Poggesi A., Inzitari D. The relation between white matter lesions and cognition // Curr. Opin. Neurol. – 2007; 20: 390–7
  33. Damulin I.V. Sosudistaja dementsija // Nevrol. zhurn. – 1999; 4: 4–11.34.
  34. Bochkarev V.K., Fajzulloev A.Z., Avedisova A.S. Effektivnost' pro-35. norana pri vozrastnom uhudshenii pamjati // Zhurn. nevrol. i psihiat. im. S.S. Korsakova. – 2005; 105 (2): 46–50.
  35. Bartoli G., Wichrowska E. Controlled clinical trial of piribedil in the treatment 36. of cerebrovascular insufficiency // La Clinica Terapeutica. – 1976; 78: 141–51.
  36. Zaharov V.V., Lokshina A.B. Primenenie preparata Pronoran (piribe-37. dil) pri legkih kognitivnyh rasstrojstvah u pozhilyh bol'nyh s distsirku-ljatornoj entsefalopatiej // Nevrol. zhurn. – 2004; 2: 30–5.
  37. Bogolepova A.N., Chukanova E.I. Dofaminergicheskaja terapija bol'nyh 38. s hronicheskoj tserebrovaskuljarnoj nedostatochnost'ju // Vrach. – 2013; 3: 25–8.
  38. Mentenopoulos G., Katsarou Z., Bostantjopoulou S. et al. Piribedil 39. Therapy 12. in Parkinson's Disease. Use of the drug in the retard form // Clin. Neuropharm. – 1989; 12: 23–8.